Anti-Human M-CSF R – Biotin
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Goat Immunogen Purified Recombinant Human M-CSF R (Accession # CAA27300) Formulation This biotinylated antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 50 µg of bovine serum albumin per µg of antibody with no calcium, magnesium, or preservatives present. State of Matter Lyophilized Storage and Handling The lyophilized, biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted biotin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months. Country of Origin USA Shipping Next Day Ambient RRIDAB_2831300 Applications and Recommended Usage? Quality Tested by Leinco Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing M-CSF R. A suggested method would be to stain cells expressing M-CSF R with 3 - 10 µg per 1 x 106 cells in a total staining volume of 100 µl followed by PN:A104. Western Blotting: To detect Human M-CSF R this biotin conjugate can be used at a concentration of 0.1 - 0.2 µg/ml. This biotin conjugate should be used in conjunction with compatible second-step reagents such as PN:A106 and a chromogenic substrate such as PN:T343. The detection limit for Human M-CSF R is 5 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:M1237. ELISA Sandwich Assay: This antibody can be used as the detection antibody in a sandwich ELISA at a concentration of approximately 0.1-0.4 µg/ml. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Goat Anti-Human Macrophage Colony Stimulating Factor Receptor (M-CSF R) recognizes Human M-CSF R. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research. Background Macrophage colony-stimulating factor (M-CSF, also termed CSF-1) receptor is an integral membrane tyrosine kinase, expressed in monocytes (macrophages and their progenitors) and drives growth and development of this blood cell lineage.1,2,3 It also triggers growth and development of mononuclear phagocytes and placental trophoblasts.4 M-CSF receptor is present in osteoclasts both at mRNA and protein levels. When M-CSF ligand specifically binds to the M-CSF receptor on osteoclasts, it induces receptor dimerization, activation and autophosphorylation of cytoplasmic tyrosine residues5 M-CSF and its receptor present as candidate therapeutic targets in states of inflammatory bone erosion.6 PubMed NCBI Gene Bank ID UniProt.org Research Area Other Molecules References & Citations1. Stanley, ER. et al. (1978) Nature 274: 168 2. Byrne, PV. et al. (1981) J. Cell. Biol. 91: 848 3. Bourette, RP. et al. (2000) Growth Factors 17: 155 4. Stanley, ER. et al. (1996) Bone 18: 355 5. Novak, U. et al. (1996) Oncogene 13: 2607 6. Teitelbaum, SL. et al. (2005) J Clin Invest. 115(12):3418-27. Technical ProtocolsELISA Det   Certificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
|---|---|
M1264 | |
M1237 | |
M1305 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
